493 related articles for article (PubMed ID: 12845688)
1. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
5. Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer.
Salminen E; Ala-Houhala M; Korpela J; Varpula M; Tiitinen SL; Halleen JM; Väänänen HK
Acta Oncol; 2005; 44(7):742-7. PubMed ID: 16227166
[TBL] [Abstract][Full Text] [Related]
6. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
7. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
[TBL] [Abstract][Full Text] [Related]
9. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
[TBL] [Abstract][Full Text] [Related]
10. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
11. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
Chao TY; Wu YY; Janckila AJ
Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
[TBL] [Abstract][Full Text] [Related]
13. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children--a novel marker for bone growth.
Chen CJ; Chao TY; Janckila AJ; Cheng SN; Ku CH; Chu DM
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):55-62. PubMed ID: 15679069
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
[TBL] [Abstract][Full Text] [Related]
16. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
18. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
19. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]